{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967021",
  "id": "02967021",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250708",
  "time": "0826",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06lkx1q0vjxddl.pdf",
  "summary": "**Material Information Summary:**  \n\n- **INN (International Non-Proprietary Name) granted** for Syntara\u2019s SNT-5505 (amsulostat), a clinical-stage drug for myelofibrosis.  \n- **Fast Track Designation** previously awarded by the FDA, reinforcing regulatory support.  \n- **Positive interim Phase 2 results** showed promising efficacy and safety in combination with ruxolitinib.  \n- **Upcoming clinical trials**: Phase 1c/2 studies in myelodysplastic syndrome expected H1 2025.  \n\n*No capital markets or trading-specific actions announced.*",
  "usage": {
    "prompt_tokens": 1383,
    "completion_tokens": 125,
    "total_tokens": 1508,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T22:45:25.826594"
}